Liposomal plasmid DNA encoding human thymosin alpha and interferon omega potently inhibits liver tumor growth in ICR mice.

Chen PF, Fu GF, Zhang HY, Xu GX, Hou YY

Journal of gastroenterology and hepatology1 Oct 2006Cited by 7 (Europe PMC)

PMID16928214DOI10.1111/j.1440-1746.2006.04536.xPepBankPUB-16928214

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with Hep-A-22 liver tumors, the dual-gene plasmid (thymosin alpha‑1 and interferon omega1) in liposomes inhibited tumor growth by 43%.
In plain wordsIn mice with liver tumors, a liposome-delivered plasmid carrying genes for thymosin alpha‑1 and interferon omega1 reduced tumor growth by 43%.
Peptide
Thymosin alpha-1
Outcome
DecreaseTumor inhibition by dual-gene plasmid
Study
mousen: not reported in source
ICR mice bearing Hep-A-22 liver tumor
Comparator
Empty vector
Outcome group
Tumor growth · Cancer
Measurements
Tumor inhibition
43%
Dual-gene plasmid
Source sentences
Summary
Only the group treated with dual-gene plasmid reached an eligible level of tumor inhibition (43%).
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the potential therapeutic effect of liposomal gene delivery, genes encoding for human thymosin alpha1 (Talpha1) and interferon omega1 were injected via the tail vein into mice bearing a Hep-A-22 liver tumor.
Summary · context
The potency of tumor inhibition was evaluated when three treated groups were compared with the group receiving the empty vector.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1692821401
02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with Hep-A-22 liver tumors, tumor weight was significantly lower in groups given the thymosin alpha‑1 gene or the interferon omega1 gene than in controls (P<0.05).
In plain wordsIn mice with liver tumors, plasmids carrying either the thymosin alpha‑1 gene or the interferon omega1 gene lowered tumor weight compared with the empty vector.
Peptide
Thymosin alpha-1
Outcome
DecreaseTumor weight with single-gene plasmids
Study
mousen: not reported in source
ICR mice bearing Hep-A-22 liver tumor
Comparator
Empty vector
Outcome group
Tumor growth · Cancer
Source sentences
Summary
The difference in tumor weight was statistically significant between the Talpha1 gene or the interferon omega1 gene treated groups and the control (P<0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the potential therapeutic effect of liposomal gene delivery, genes encoding for human thymosin alpha1 (Talpha1) and interferon omega1 were injected via the tail vein into mice bearing a Hep-A-22 liver tumor.
Summary · context
The potency of tumor inhibition was evaluated when three treated groups were compared with the group receiving the empty vector.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1692821402
03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with Hep-A-22 liver tumors, tumor weight was highly significantly lower with the dual-gene plasmid than in controls (P<0.01).
In plain wordsIn mice with liver tumors, the plasmid carrying both genes lowered tumor weight more clearly than the empty vector.
Peptide
Thymosin alpha-1
Outcome
DecreaseTumor weight with dual-gene plasmid
Study
mousen: not reported in source
ICR mice bearing Hep-A-22 liver tumor
Comparator
Empty vector
Outcome group
Tumor growth · Cancer
Source sentences
Summary
and highly significant between the dual-gene treated group and the control (P<0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the potential therapeutic effect of liposomal gene delivery, genes encoding for human thymosin alpha1 (Talpha1) and interferon omega1 were injected via the tail vein into mice bearing a Hep-A-22 liver tumor.
Summary · context
The potency of tumor inhibition was evaluated when three treated groups were compared with the group receiving the empty vector.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1692821403
04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism
A DNA ladder, a sign of apoptosis, was seen in tumor cells from mice treated with the gene constructs but not from controls.
In plain wordsIn mice, tumor cells from animals given the gene plasmids showed signs of programmed cell death, unlike control tumors.
Peptide
Thymosin alpha-1
Outcome
IncreaseDNA fragmentation (apoptosis) in tumor cells
Study
mousen: not reported in source
ICR mice bearing Hep-A-22 liver tumor
Comparator
Empty vector
Outcome group
Tumor growth · Cancer
Source sentences
Summary
DNA ladder was observed in the tumor cells from the purpose gene treated groups but not from the control.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the potential therapeutic effect of liposomal gene delivery, genes encoding for human thymosin alpha1 (Talpha1) and interferon omega1 were injected via the tail vein into mice bearing a Hep-A-22 liver tumor.
Summary · context
The potency of tumor inhibition was evaluated when three treated groups were compared with the group receiving the empty vector.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1692821404
05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice, the dual-gene plasmid-liposome complex inhibited growth of Hep-A-22 tumor cells more potently than the single gene constructs.
In plain wordsIn mice, the plasmid with both genes slowed liver tumor growth more than plasmids with one gene.
Peptide
Thymosin alpha-1
Outcome
DecreaseDual-gene versus single-gene tumor inhibition
Study
mousen: not reported in source
ICR mice bearing Hep-A-22 liver tumor
Comparator
Single-gene constructs
Outcome group
Tumor growth · Cancer
Source sentences
Summary
The dual-gene plasmid-liposome complex showed more potent inhibition than the single gene constructs on the growth of Hep-A-22 tumor cells in mice
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the potential therapeutic effect of liposomal gene delivery, genes encoding for human thymosin alpha1 (Talpha1) and interferon omega1 were injected via the tail vein into mice bearing a Hep-A-22 liver tumor.
Summary · context
The potency of tumor inhibition was evaluated when three treated groups were compared with the group receiving the empty vector.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1692821405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.